Absorb生物可吸收血管支架5年随访的时变结局:系统Meta分析与个体患者数据汇总研究
该研究汇总4项随机临床试验共3384例冠心病患者个体数据,比较Absorb生物可吸收血管支架(BVS)与依维莫司洗脱支架(EES)的5年结局。结果显示BVS组5年内靶病变失败和器械血栓发生率均高于EES组,但超额风险主要集中在0至3年,3至5年期间两组事件率无显著差异。
要点
- BVS超额风险集中于0至3年,3至5年期间两组靶病变失败和器械血栓风险无显著差异。
核心结论
- 第一代Absorb BVS的超额风险期在3年时结束,3至5年期间BVS与EES的靶病变失败和器械血栓风险无显著差异。
研究设计与样本
- 系统Meta分析与个体患者数据汇总研究,纳入4项BVS vs EES随机临床试验,共3384例冠心病患者,随访至少5年。
主要发现
- 样条分析及多重插补和多变量分析后结果一致。
临床怎么用
- 第一代Absorb BVS的临床风险在植入后3年内尤为突出,需加强该时段内的监测与抗血栓管理。
- 3年后BVS事件风险与EES相当,但生物可吸收支架技术仍需克服早期安全性障碍才能作为冠心病的有效替代选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Bioresorbable scaffolds were designed to provide clinical benefits after their complete bioresorption. Prior studies demonstrated early risks with the Absorb polymeric bioresorbable vascular scaffold (BVS). Whether this risk profile changes over time during the course of its bioresorption is unknown. OBJECTIVE: To examine outcomes of the first-generation BVS before and after 3 years, the point of its complete bioresorption in animals. DATA SOURCES: We searched MEDLINE and the Cochrane database, conference proceedings, and public websites for relevant studies. STUDY SELECTION: Eligible studies were randomized clinical trials of BVS vs metallic drug-eluting stents in patients with coronary artery disease with at least 5-year follow-up. Four trials of BVS vs everolimus-eluting stents (EES) with 3384 patients met criteria. DATA EXTRACTION AND SYNTHESIS: Individual patient data from the 4 trials were pooled, and summary-level meta-analysis was performed. MAIN OUTCOMES AND MEASURES: The major effectiveness and safety measures were target lesion failure (TLF; cardiac death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization) and device thrombosis. Outcomes were examined through 5-year follow-up and between 0 to 3 and 3 to 5 years. RESULTS: Mean age for the 3384 patients was 62.8 years; 2452 patients were men (72.5%), and diabetes was present in 1020 patients (30.2%). Through 5-year follow-up, treatment with BVS compared with EES was associated with higher rates of TLF (14.9% vs 11.6%; HR, 1.26; 95% CI, 1.03-1.54; P = .03) and device thrombosis (2.5% vs 0.8%; HR, 2.87; 95% CI, 1.46-5.65; P = .002). Target lesion failure occurred in 11.6% of BVS-treated patients vs 7.9% of EES-treated patients between 0 to 3 years (HR, 1.42; 95% CI, 1.12-1.80), and 4.3% of BVS-treated patients vs 4.5% of EES-treated patients between 3 to 5 years (HR, 0.92; 95% CI, 0.64-1.31) (P for interaction = .046). Device thrombosis occurred in 2.4% of BVS-treated patients vs 0.6% of EES-treated patients between 0 to 3 years (HR, 3.86; 95% CI, 1.75-8.50) and 0.1% of BVS-treated patients vs 0.3% of EES-treated patients between 3 to 5 years (HR, 0.44; 95% CI, 0.07-2.70) (P for interaction = .03). These results were consistent by spline analysis and after multiple imputation and multivariable analysis. CONCLUSIONS AND RELEVANCE: The period of excess risk for the first-generation Absorb BVS ends at 3 years. These data provide mechanistic insights into the timing of adverse events after BVS and identify the hurdles to be overcome for bioresorbable technology to be accepted as a valid alternative for patients with coronary artery disease. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT01751906, NCT01844284, NCT01923740, and NCT01425281.
引用
- Stone GW, Kimura T, Gao R, et al. Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study. JAMA Cardiol. 2019. PMID: 31561250. doi:10.1001/jamacardio.2019.4101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。